StockData
AbbVie Inc. logo

AbbVie Inc. (ABBV) stock

ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/3090% above fair value
$294.55−0.48 (-0.16%)

Close on Nov 16, 2026Market cap $520.50BP/E 83.2Yield 2.26%

AbbVie total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

AbbVie's total debt was $70.82B at Jun 30, 2026. For fiscal 2025 it was $67.50B, up 0.5% from the year before. Over ten years it grew 7.9% a year on average. The highest annual figure on record is $86.06B in fiscal 2020.

Annual total debt

PeriodPeriod endValueChange
FY2025Dec 31, 2025$67.50B+0.5%
FY2024Dec 31, 2024$67.14B+13.1%
FY2023Dec 31, 2023$59.39B-6.1%
FY2022Dec 31, 2022$63.27B-17.5%
FY2021Dec 31, 2021$76.68B-10.9%
FY2020Dec 31, 2020$86.06B+29.0%
FY2019Dec 31, 2019$66.73B+65.5%
FY2018Dec 31, 2018$40.31B+7.9%
FY2017Dec 31, 2017$37.37B+1.4%
FY2016Dec 31, 2016$36.84B+16.3%
FY2015Dec 31, 2015$31.67B+111.5%
FY2014Dec 31, 2014$14.98B+1.7%
FY2013Dec 31, 2013$14.72B-6.1%
FY2012Dec 31, 2012$15.67B–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$70.82B+0.5%
Q1 FY2026Mar 31, 2026$72.86B+4.2%
Q4 FY2025Dec 31, 2025$67.50B+0.5%
Q3 FY2025Sep 30, 2025$68.74B-3.3%
Q2 FY2025Jun 30, 2025$70.48B-0.2%
Q1 FY2025Mar 31, 2025$69.89B-5.6%
Q4 FY2024Dec 31, 2024$67.14B+13.1%
Q3 FY2024Sep 30, 2024$71.08B+17.0%
Q2 FY2024Jun 30, 2024$70.63B+15.8%
Q1 FY2024Mar 31, 2024$74.00B+19.2%
Q4 FY2023Dec 31, 2023$59.39B-6.1%
Q3 FY2023Sep 30, 2023$60.75B-12.7%
Q2 FY2023Jun 30, 2023$61.02B-16.3%
Q1 FY2023Mar 31, 2023$62.09B-15.5%
Q4 FY2022Dec 31, 2022$63.27B-17.5%
Q3 FY2022Sep 30, 2022$69.61B-13.8%
Q2 FY2022Jun 30, 2022$72.93B-11.2%
Q1 FY2022Mar 31, 2022$73.47B-14.1%
Q4 FY2021Dec 31, 2021$76.68B-10.9%
Q3 FY2021Sep 30, 2021$80.72B-7.3%
Q2 FY2021Jun 30, 2021$82.14B-6.1%
Q1 FY2021Mar 31, 2021$85.53B+27.6%
Q4 FY2020Dec 31, 2020$86.06B+29.0%
Q3 FY2020Sep 30, 2020$87.06B+126.7%
Q2 FY2020Jun 30, 2020$87.43B+134.7%
Q1 FY2020Mar 31, 2020$67.05B+80.5%
Q4 FY2019Dec 31, 2019$66.73B+65.5%
Q3 FY2019Sep 30, 2019$38.40B-5.2%
Q2 FY2019Jun 30, 2019$37.26B+0.4%
Q1 FY2019Mar 31, 2019$37.14B-0.4%
Q4 FY2018Dec 31, 2018$40.31B+7.9%
Q3 FY2018Sep 30, 2018$40.51B+7.2%
Q2 FY2018Jun 30, 2018$37.11B-0.3%
Q1 FY2018Mar 31, 2018$37.29B+0.9%
Q4 FY2017Dec 31, 2017$37.37B+1.4%
Q3 FY2017Sep 30, 2017$37.80B+1.3%
Q2 FY2017Jun 30, 2017$37.24B–
Q1 FY2017Mar 31, 2017$36.95B–
Q4 FY2016Dec 31, 2016$36.84B–
Q3 FY2016Sep 30, 2016$37.31B–

More AbbVie figures

See a number that looks wrong?